Hydroxychloroquine sulphate therapy of erosive oral lichen planus.
Adult
Aged
Aged, 80 and over
Creatinine
/ blood
Exanthema
/ chemically induced
Female
Humans
Hydroxychloroquine
/ therapeutic use
Hyperpigmentation
/ chemically induced
Immunologic Factors
/ therapeutic use
Lichen Planus, Oral
/ drug therapy
Male
Middle Aged
Remission Induction
Vision Disorders
/ chemically induced
Visual Analog Scale
erosive
hydroxychloroquine
lichen planus
oral
therapy
Journal
The Australasian journal of dermatology
ISSN: 1440-0960
Titre abrégé: Australas J Dermatol
Pays: Australia
ID NLM: 0135232
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
received:
31
08
2018
accepted:
29
09
2018
pubmed:
10
11
2018
medline:
18
12
2019
entrez:
10
11
2018
Statut:
ppublish
Résumé
Erosive oral lichen planus (LP) may be painful and debilitating. Symptomatic oral LP has been treated with a wide spectrum of topical and systemic therapies, but few have been evaluated in large series. Hydroxychloroquine is suggested to be effective in oral LP. Twenty-one consecutive patients with erosive, biopsy-confirmed oral LP were prescribed. hydroxychloroquine sulphate 400 mg/day. Symptomatic improvement was evaluated by means of a visual analogue scale into three groups: no change, moderate to marked improvement and complete remission. Five (24%) patients obtained complete remission, 12 (57%) patients showed moderate to marked improvement, 3 (14%) patients did not improve at all and in one patient therapy was terminated after 1 month due to side effects. Response to therapy was observed after 2-4 months. Side effects which ultimately led to termination of therapy in three patients were elevated creatinine serum levels (after 1 month), visual field defects (after 8 months) and hyperpigmentation (after 24 months). Among six patients who responded to therapy, three flared on stopping. Hydroxychloroquine sulphate may be effective and relatively safe treatment for erosive oral LP.
Sections du résumé
BACKGROUND/OBJECTIVES
OBJECTIVE
Erosive oral lichen planus (LP) may be painful and debilitating. Symptomatic oral LP has been treated with a wide spectrum of topical and systemic therapies, but few have been evaluated in large series. Hydroxychloroquine is suggested to be effective in oral LP.
METHODS
METHODS
Twenty-one consecutive patients with erosive, biopsy-confirmed oral LP were prescribed. hydroxychloroquine sulphate 400 mg/day. Symptomatic improvement was evaluated by means of a visual analogue scale into three groups: no change, moderate to marked improvement and complete remission.
RESULTS
RESULTS
Five (24%) patients obtained complete remission, 12 (57%) patients showed moderate to marked improvement, 3 (14%) patients did not improve at all and in one patient therapy was terminated after 1 month due to side effects. Response to therapy was observed after 2-4 months. Side effects which ultimately led to termination of therapy in three patients were elevated creatinine serum levels (after 1 month), visual field defects (after 8 months) and hyperpigmentation (after 24 months). Among six patients who responded to therapy, three flared on stopping.
CONCLUSIONS
CONCLUSIONS
Hydroxychloroquine sulphate may be effective and relatively safe treatment for erosive oral LP.
Substances chimiques
Immunologic Factors
0
Hydroxychloroquine
4QWG6N8QKH
Creatinine
AYI8EX34EU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e109-e112Informations de copyright
© 2018 The Australasian College of Dermatologists.